UnknownNot Applicable

Pulmonary Artery Denervation in Patients With Atrial Fibrillation and Group 2 of Pulmonary Hypertension

Russia116 participantsStarted 2023-05-22

Plain-language summary

The goal of the study is to compare efficacy and safety of the pulmonary artery denervation procedure combined with atrial fibrillation ablation versus atrial fibrillation ablation alone in patients with paroxysmal and persistent atrial fibrillation and group 2 of the pulmonary hypertension

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Mean pulmonary artery pressure \> 25 mm Hg and pulmonary artery wedge pressure \> 15 mm Hg by right heart catheterization * Paroxysmal or persistent atrial fibrillation * NYHA II-III * BNP \> 105 pg/ml * Indications for catheter ablation of atrial fibrillation according guidelines * LVEF \> 50% Exclusion Criteria: * Group 1,3,4 of the pulmonary hypertension * Left atrium diameter \> 6 cm * Planned open heart surgery procedure * Previous heart valve surgery * Severe aortic, pulmonary, tricuspid or mitral, valves regurgitation * Thrombus in the left heart chambers

What they're measuring

Freedom from Atrial Fibrillation/Atrial Flutter/Atrial Tachycardia

Timeframe: 12 months

Trial details

NCT IDNCT05856461

SponsorMeshalkin Research Institute of Pathology of Circulation

Sponsor typeNETWORK

Study typeINTERVENTIONAL

Primary completion2024-12-29

Contact for this trial

Alexander Romanov, MD

+73833327655 abromanov@mail.ru

View on ClinicalTrials.gov More Atrial Fibrillation trials